- Home
- CLRO vs NXL Comparison
CLRO vs NXL Comparison
Compare CLRO & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLRO | NXL |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 7.5M |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CLRO | NXL |
|---|---|---|
| Price | $5.00 | $7.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 686.9K | 12.4K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $46,067,000.00 | $301,647.00 |
| Revenue This Year | N/A | $14.37 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 11.59 | ★ 78.78 |
| 52 Week Low | $2.71 | $0.22 |
| 52 Week High | $16.50 | $7.69 |
Technical Indicators
Market Signals| Indicator | CLRO | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 53.79 | 75.97 |
| Support Level | $4.47 | $0.36 |
| Resistance Level | $6.42 | $7.69 |
| Average True Range (ATR) | 0.60 | 0.53 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 69.55 | 69.14 |
Price Performance
Historical ComparisonAbout CLRO ClearOne Inc. (DE)
ClearOne Inc is currently engaged in activities that consist solely of fulfilling warranty and technical support obligations on legacy products, evaluating potential Strategic Transactions, managing and liquidating remaining assets of the company's legacy operating business, collecting accounts receivable and recovering prepaid assets, satisfying outstanding liabilities, and maintaining public-company compliance.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.